BOLD Boundless Bio Inc Gross Profit Margin

BOLD (Boundless Bio Inc.) - company brandmark

Boundless Bio, Inc. (BOLD) is expanding its share of the precision oncology market, as evidenced by gross margin dynamics based on GURU.Markets chart data, where the indicator stands at 0.00. High profitability is driven by a patent monopoly on cancer treatment. The trend's stability is underpinned by a unique scientific foundation and significant bioinformatics expenditures, creating a robust defensive barrier for the business.

BOLD (Boundless Bio) Gross Margin history from 03/29/2024 to 11/19/2026

Financial and market metric breakdowns for boundlessbio.com (BOLD)

- current quotes and average value forecast:
Summary company analysis:BOLD - Boundless Bio
Brand item of Boundless Bio, Inc.

An investment audit of Boundless Bio, Inc. (BOLD) requires an analysis of the gross margin, calculated as the ratio of the difference between revenue and cost of goods sold to total sales, to evaluate production efficiency. In the context of developing unique ecDNA therapies, this metric reflects the company's ability to monetize innovations in the fight against aggressive cancer, clearly demonstrating the profitability of its implementation.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Margin CDXS (Codexis, Inc.)|SGMO: Gross Return on Sales|Nautilus Biotechnology - Gross Margin|Gross Profit Rate MGX (Metagenomi, Inc)|DTIL: Gross Margin|GBIO: Gross Profit Ratio|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability